The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

Vector Solutions, the leading provider of technology solutions to help train, prepare, and retain public safety professionals, is amplifying its commitment to firefighter health and safety with a ...

Pharmaceuticals and vector-control programmes have greatly diminished the once-widespread disease, but sustained effort will ...

Yun Zhong, an analyst from Wedbush, maintained the Buy rating on Rocket Pharmaceuticals (RCKT – Research Report). The associated price target ...

KLS-1 is under clinical development by Vector Vitale and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II drugs for Metastatic Melanoma have a 36% phase transition ...

A phase 3 trial highlights betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β ...